Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients.

Abstract

Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease characterized by AE resistant to antihistamines and a chronic course. We report five new cases of InH-AAE (two women and three men) with a rapid and dramatic response to the anti-immunoglobulin-E antibody omalizumab. In our literature review, we found 13 other relevant cases with a good response to this treatment. Overall, in 6 out of 18 patients, the doses of omalizumab required to prevent recurrences of attacks were higher than the licensed dose for chronic urticaria. No significant adverse effects have been reported.

• Authors: Charles Faisant, Aurélie Du Thanh, Catherine Mansard, Alban Deroux, Isabelle Boccon-Gibod, Laurence Bouillet
• Journal: Journal of clinical immunology (J Clin Immunol) Vol. 37 Issue 1 Pg. 80-84 (01 2017) ISSN: 1573-2592 [Electronic] Netherlands
• PMID: 27826875 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Anti-Allergic Agents
• Biomarkers
• Histamine H1 Antagonists
• Omalizumab
• Immunoglobulin E

Topics

• Adult
• Aged, 80 and over
• Angioedema (diagnosis, drug therapy, etiology, metabolism)
• Anti-Allergic Agents (administration & dosage, therapeutic use)
• Biomarkers
• Disease Progression
• Female
• Histamine H1 Antagonists (administration & dosage, therapeutic use)
• Humans
• Immunoglobulin E (blood, immunology)
• Male
• Middle Aged
• Omalizumab (administration & dosage, therapeutic use)
• Symptom Assessment
• Treatment Outcome